D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
NVIDIA
NVDA
|
+$1.29B |
| 2 |
Apple
AAPL
|
+$1.22B |
| 3 |
T-Mobile US
TMUS
|
+$889M |
| 4 |
Micron Technology
MU
|
+$887M |
| 5 |
Netflix
NFLX
|
+$828M |
Top Sells
| 1 |
Robinhood
HOOD
|
+$1.02B |
| 2 |
GE Vernova
GEV
|
+$976M |
| 3 |
Charles Schwab
SCHW
|
+$582M |
| 4 |
TSMC
TSM
|
+$572M |
| 5 |
Microsoft
MSFT
|
+$564M |
Sector Composition
| 1 | Technology | 23.26% |
| 2 | Healthcare | 12.06% |
| 3 | Consumer Discretionary | 11.62% |
| 4 | Financials | 9.02% |
| 5 | Industrials | 9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
FSP
2101
Franklin Street Properties
FSP
$174M
| $1.01M | ﹤0.01% |
615,113
-100,803
| -14% | -$165K |
|
|
WTGUU
2102
Wintergreen Acquisition Corp. Unit
WTGUU
$53.3M
| $1.01M | ﹤0.01% |
+100,000
| New | +$1.01M |
|
2103
Orthofix Medical
OFIX
$589M
| $1.01M | ﹤0.01% |
90,333
+37,953
| +72% | +$423K |
|
2104
Sable Offshore Corp
SOC
$2.3B
| $1.01M | ﹤0.01% |
45,758
+30,888
| +208% | +$679K |
|
2105
Las Vegas Sands
LVS
$36.7B
| $1M | ﹤0.01% |
+23,086
| New | +$1M |
|
2106
Willdan Group
WLDN
$1.48B
| $1M | ﹤0.01% |
16,046
-9,151
| -36% | -$572K |
|
2107
ARS Pharmaceuticals
SPRY
$991M
| $1M | ﹤0.01% |
57,449
+23,652
| +70% | +$413K |
|
2108
GCM Grosvenor Inc. Warrant
GCMGW
$32.3M
| $1M | ﹤0.01% |
1,562,787
| – | – |
|
2109
United States Lime & Minerals
USLM
$3.63B
| $998K | ﹤0.01% |
10,002
-16,701
| -63% | -$1.67M |
|
|
AFCG
2110
AFC Gamma
AFCG
$105M
| $996K | ﹤0.01% |
222,399
-11,310
| -5% | -$50.7K |
|
2111
Trinseo
TSE
$87.7M
| $987K | ﹤0.01% |
316,474
-69,306
| -18% | -$216K |
|
2112
Origin Bancorp
OBK
$1.11B
| $985K | ﹤0.01% |
+27,557
| New | +$985K |
|
2113
Lands' End
LE
$475M
| $978K | ﹤0.01% |
91,280
-21,888
| -19% | -$234K |
|
2114
Kaiser Aluminum
KALU
$1.24B
| $975K | ﹤0.01% |
12,205
-44,013
| -78% | -$3.52M |
|
2115
BRC Inc
BRCC
$183M
| $972K | ﹤0.01% |
742,133
+286,973
| +63% | +$376K |
|
2116
Amylyx Pharmaceuticals
AMLX
$1.24B
| $971K | ﹤0.01% |
151,502
-118,504
| -44% | -$760K |
|
2117
Arcosa
ACA
$4.67B
| $966K | ﹤0.01% |
11,136
+4,794
| +76% | +$416K |
|
2118
OneSpaWorld
OSW
$2.24B
| $962K | ﹤0.01% |
47,184
-101,978
| -68% | -$2.08M |
|
2119
Marqeta
MQ
$2.61B
| $962K | ﹤0.01% |
+165,014
| New | +$962K |
|
2120
WD-40
WDFC
$2.86B
| $962K | ﹤0.01% |
4,216
-7,404
| -64% | -$1.69M |
|
2121
Patterson-UTI
PTEN
$2.13B
| $961K | ﹤0.01% |
161,990
+70,880
| +78% | +$420K |
|
2122
Vanguard Mid-Cap ETF
VO
$88B
| $958K | ﹤0.01% |
+3,425
| New | +$958K |
|
2123
Immunovant
IMVT
$2.82B
| $957K | ﹤0.01% |
59,818
+9,284
| +18% | +$149K |
|
2124
Ocular Therapeutix
OCUL
$2.23B
| $954K | ﹤0.01% |
102,833
+42,710
| +71% | +$396K |
|
2125
W.P. Carey
WPC
$15B
| $953K | ﹤0.01% |
15,285
+4,820
| +46% | +$301K |
|